文献速递临床试验与 GCP基础与转化研究

LentiGlobin治疗镰状细胞病的生物学与临床疗效

Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease.
PubMed 文献 · N Engl J Med · 2021-12-12

这项正在进行的1-2期研究在C组35例镰状细胞病患者中评估LentiGlobin的安全性和疗效,纳入标准为入组前24个月内至少4次严重血管闭塞事件。截至2021年2月,中位随访17.3个月,全部35例均实现植入;可评估的25例患者严重血管闭塞事件全部消退,溶血标志物下降,未观察到血液系统恶性肿瘤。

要点

  • 可评估的25例患者严重血管闭塞事件全部消退,而基线中位为每年3.5次。
  • 中位总血红蛋白从基线8.5 g/dl升至输注后6至36个月期间的11 g/dl以上。
  • HbAT87Q占总血红蛋白至少40%,分布于平均85±8%的红细胞。

核心结论

  • 一次性LentiGlobin治疗在大多数红细胞中实现HbAT87Q的持续产生,导致溶血减少和严重血管闭塞事件完全消退。

研究设计与样本

  • 正在进行的1-2期研究,最初在A组7例和B组2例患者中优化治疗流程,随后设立C组用于关键性评估。
  • C组采用更严格的纳入标准,要求入组前24个月内至少4次严重血管闭塞事件。
  • 本次为未预先设定的中期分析,评估C组35例患者的安全性和疗效。
  • 疗效分析纳入入组前24个月内至少4次血管闭塞事件且随访至少6个月的患者。
  • 截至2021年2月,C组43例已启动细胞采集,其中35例接受了LentiGlobin输注,中位随访17.3个月(范围3.7至37.6)。

主要发现

  • 全部35例患者均实现植入。
  • 中位总血红蛋白水平从基线8.5 g/dl升至输注后6至36个月期间的11 g/dl以上。
  • HbAT87Q占总血红蛋白至少40%,分布于平均(±SD)85±8%的红细胞。
  • 溶血标志物降低。
  • 可评估的25例患者严重血管闭塞事件全部消退,而入组前24个月内中位为每年3.5次(范围2.0至13.5)。

关键数值与推荐

  • C组纳入标准:入组前24个月内至少4次严重血管闭塞事件。
  • 疗效分析条件:入组前24个月内至少4次血管闭塞事件且随访至少6个月。
  • 截至2021年2月,C组43例启动细胞采集,35例接受输注。

局限性

  • 本次为未预先设定的中期分析。
  • 中位随访17.3个月,范围3.7至37.6个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sickle cell disease is characterized by the painful recurrence of vaso-occlusive events. Gene therapy with the use of LentiGlobin for sickle cell disease (bb1111; lovotibeglogene autotemcel) consists of autologous transplantation of hematopoietic stem and progenitor cells transduced with the BB305 lentiviral vector encoding a modified β-globin gene, which produces an antisickling hemoglobin, HbAT87Q. METHODS: In this ongoing phase 1-2 study, we optimized the treatment process in the initial 7 patients in Group A and 2 patients in Group B with sickle cell disease. Group C was established for the pivotal evaluation of LentiGlobin for sickle cell disease, and we adopted a more stringent inclusion criterion that required a minimum of four severe vaso-occlusive events in the 24 months before enrollment. In this unprespecified interim analysis, we evaluated the safety and efficacy of LentiGlobin in 35 patients enrolled in Group C. Included in this analysis was the number of severe vaso-occlusive events after LentiGlobin infusion among patients with at least four vaso-occlusive events in the 24 months before enrollment and with at least 6 months of follow-up. RESULTS: As of February 2021, cell collection had been initiated in 43 patients in Group C; 35 received a LentiGlobin infusion, with a median follow-up of 17.3 months (range, 3.7 to 37.6). Engraftment occurred in all 35 patients. The median total hemoglobin level increased from 8.5 g per deciliter at baseline to 11 g or more per deciliter from 6 months through 36 months after infusion. HbAT87Q contributed at least 40% of total hemoglobin and was distributed across a mean (±SD) of 85±8% of red cells. Hemolysis markers were reduced. Among the 25 patients who could be evaluated, all had resolution of severe vaso-occlusive events, as compared with a median of 3.5 events per year (range, 2.0 to 13.5) in the 24 months before enrollment. Three patients had a nonserious adverse event related or possibly related to LentiGlobin that resolved within 1 week after onset. No cases of hematologic cancer were observed during up to 37.6 months of follow-up. CONCLUSIONS: One-time treatment with LentiGlobin resulted in sustained production of HbAT87Q in most red cells, leading to reduced hemolysis and complete resolution of severe vaso-occlusive events. (Funded by Bluebird Bio; HGB-206 ClinicalTrials.gov number, NCT02140554.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Kanter J, Walters MC, Krishnamurti L, et al. Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease. N Engl J Med. 2021. PMID: 34898139. doi:10.1056/NEJMoa2117175

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。